01. TechnologyProTransMilestones AchievedStudy TeamFirst indication: Type-1 DiabetesCellaviva
02. About NextCellBusiness ConceptHistory
MarketOrganisationCompany Structure
03. InvestorsFinancial CalendarFinancial ReportsCorporate GovernanceCertified AdviserThe ShareArchive
04. NewsPress ReleasesNewsCompany PresentationsCompany Analyses
05. ContactContact InformationSubscribe
English
/
Svenska

Part of the
Stem Cell Revolution

Stem cells are expected to revolutionize the treatment of today's severe and incurable diseases. NextCell develops pioneering stem cell therapies for the treatment of autoimmune and inflammatory diseases as well as for use in organ transplants.

Technology

NextCell develops ProTrans™, a drug candidate consisting of stem cells for the treatment of autoimmune diseases, initially focusing on type- 1 diabetes. ProTrans is based on NextCell patent pending Selection Algorithm. Further, NextCell runs Cellaviva, Nordic's largest private stem cell bank, approved by IVO.
Read more

ProTrans shows significant effect in Diabetes

NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved preservation of insulin production over 12 months, compared to patients treated with placebo (p-value < 0.05).

Read more

About NextCell

NextCell is a Swedish biopharmaceutical company running two business areas with the same core – stem cells from umbilical cord. NextCell is focusing on research and development of novel stem cell therapies and is also running a tissue establishment and primary biobank, classified as healthcare provider.
Read more

Investors

NextCell is listed on the Nasdaq First North Growth Market. Here you will find information about the share, the latest reports and other financial data.
Read more
Read our latest report:
Q2 Report, 2020/2021
Download

News

2021-06-10

COVID-19 patient treated with ProTrans

NextCell Pharma AB (“NextCell” or “the Company”) announces that the first patient with severe pneumonia, as a result of COVID-19 infection, has now been treated with ProTrans. The patient was hospitalized at Örebro University Hospital, where the phase 1b study ProTrans19+SE is in progress led by ...
Read more
2021-06-08

Article about Gene and Cell Therapy

Professor Edvard Smith, CMO NextCell Pharma AB ("NextCell" or the "Company") has written a review article in the Swedish Medical Journal (Läkartidningen) entitled "Gene therapy now comes in many medical specialties", together with Associate Professor Pontus Blomberg, Director of Operations; both ...
Read more
2021-05-28

NextCell presents their latest phase II clinical data at ISCT 2021

NextCell Pharma AB (“NextCell”) announces today that they will present their findings from their Phase I/II study entitled “Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes” (NCT 03406585) at the International Society of Cell and Gene The...
Read more
2021-05-26

Study start for ProTrans in COVID-19

NextCell Pharma AB (“NextCell”) announces today that both the Canadian and Swedish COVID-19 studies have been initiated and are now ready to include patients with severe pneumonia triggered by SARS-CoV-2 infection. The treatment is aimed at patients who are hospitalized and with a high risk of ne...
Read more
All news